Inhibition of the p50 (NFκB1) subunit of NF-κB by phosphorothioate- modified antisense oligodeoxynucleotides reduces NF-κB expression and immunoglobulin synthesis in murine B cells

Clinical Immunology and Immunopathology

Volumn 83, Issue 3, 1997, Pages 254-263

  Khaled, Annette R ^a   Soares, Ligia S ^b   Butfiloski, Edward J ^b   Stekman, Ivan ^b   Sobel, Eric S ^b   Schiffenbauer, Joel ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P50; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; AUTOANTIBODY; DIAGNOSTIC AGENT; DNA; IMMUNOGLOBULIN; NUCLEOTIDE;

ANIMAL CELL; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; DIAGNOSIS; IMMUNOGLOBULIN PRODUCTION; IMMUNOREGULATION; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TARGETING; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSCRIPTION REGULATION; ANIMAL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SPLEEN;

ANIMALS; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DNA; IMMUNOGLOBULINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED C57BL; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; OLIGONUCLEOTIDES, ANTISENSE; SPLEEN; THIONUCLEOTIDES; TUMOR CELLS, CULTURED;

EID: 0031150163     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1997.4354     Document Type: Article

References (33)

1. Zamecnik P. C., Stephenson M. L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligonucleotide. Proc. Natl. Acad. Sci. USA. 75:1978;280-284.
2. Stein C. A., Cheng Y.-C. Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science. 261:1993;1004-10012.
3. Brysch W., Schlingensiepen K. Design and application of antisense oligonucleotides in cell culture, in vivo and as therapeutic agents. Cell Mol. Neurobiol. 14:1994;557-568.
4. Milligan J. F., Matteucci M. D., Martin J. C. Current concepts in antisense drug design. J. Med. Chem. 36:1993;1923-1937.
5. Stein C. A., Tonkinson J. L., Yakubov L. Phosphorothioate oligodeoxynucleotides-antisense inhibitors of gene expression. Pharm. Ther. 52:1991;365-384.
6. Wagner R. W. Gene inhibition using antisense oligonucleotides. Nature. 372:1994;333-335.
7. Steinberg A. D., Krieg A. M., Takashi T., Gourley M. F. Timing of immunosuppression in the natural history of autoimmune diseases. J. Autoimmun. 5:1992;197-203.
8. Crooke S. T. Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol. 32:1992;329-376.
9. Brown D. A., Kang S., Gryaznov S. M., DeDionisio L., Heidenreich O., Sullivan S., Xu X., Nerenberg M. I. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 269:1994;26801-26805.
10. Sen R., Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancers. Cell. 46:1986;705-716.
11. Baueuerle P. A., Henkel T. Function and activation of NF-κB in the immune system. Annu. Rev. Immunol. 12:1994;141-179.
12. Finco T. S., Baldwin A. S. Mechanistic aspects of NF-κB regulation: The emerging role of phosphorylation and proteolysis. Immunity. 3:1995;263-272.
13. Hohmann H., Remy R., Scheidereit C., van Loon A. P. G. M. Maintenance of NF-κB activity is dependent on protein synthesis and the continuous presence of external stimuli. Mol. Cell. Biol. 11:1991;259-266.
14. Liu J., Chiles T. R. S., Rothstein T. L. Inducible nuclear expression of NF-κB in primary B cells stimulated through the surface Ig receptor. J. Immunol. 146:1991;1685-1691.
15. Narayanan R., Higgins K. A., Perez J. R., Coleman T. A., Rosen C. A. Evidence for differential functions of the p50 and p65 subunits of NF-κB with a cell adhesion model. Mol. Cell. Biol. 13:1993;3802-3810.
16. Sokoloski J. A., Sartorelli A. C., Rosen C. A., Narayanan R. Antisense oligonucleotides to the p65 subunit of NF-κB block CD11b expression and alter adhesion properties of differentiated HL-60 granulocytes. Blood. 82:1993;625-632.
17. Higgins K. A., Perez J. R., Coleman T. A., Dorshkind K., McComas W. A., Sarmiento U. M., Rosen C. A., Narayanan R. Antisense inhibition of the p65 subunit of NF-κB blocks tumorgenicity and causes tumor regression. Proc. Natl. Acad. Sci. USA. 90:1993;9901-9905.
18. Kitajima I., Shinohara T., Bilakovics J., Brown D. A., Xu X., Nerenberg M. Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-κB. Science. 258:1992;1792-1795.
19. Sha W. C., Liou H. C., Tuomanen E. I., Baltimore D. Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses. Cell. 80:1995;321-330.
20. Matsukura M., Shinozuka K., Zon G., Mitsuya H., Reitz M., Cohen J. S., Broder S. Phosphorothioate analogs of oligodeoxynucleotides: Inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA. 84:1987;7706-7710.
21. Boyd A. W., Goding J. W., Schrader J. W. The regulation of growth and differentiation of a murine B cell lymphoma. J. Immunol. 126:1981;2461-2465.
22. Merino R., Fossati L., Izui S. The lupus-prone BXSB strain: TheYaa. Springer Semin. Immunopathol. 14:1992;141-157.
23. Costello R., Cerdan C., Lipcey C., Algarte M., Martin Y., Baeuerle P. A., Olive D., Imbert J. The role of NF-κB1 (p50/p105) gene expression in activation of human blood T-lymphocytes via CD2 and CD28 adhesion molecules. Cell Growth Diff. 4:1993;947-954.
24. Krieg A. M., Gmeling-Meyling F., Gourley M. F., Kisch W. J., Chrisey L. A., Steinberg A. D. Uptake of oligodeoxynucleotides by lymphoid cells is heterogenous and inducible. Antisense Res. Dev. 1:1991;161-171.
25. Dignam J. D., Lebovitz R. M., Roeder R. G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acid Res. 11:1983;1475-1489.
26. Trede N. S., Castigli E., Geha R. S., Chatila T. Microbial superantigens induce NF-κB in the human monocytic cell line THP-1. J. Immunol. 150:1993;5604-5613.
27. Emlen W., Jarasiripipat P., Burdick G. A new ELISA for the detection of double-stranded DNA antibodies. J. Immunol. Methods. 132:1990;91-101.
28. Kitani A., Hara M., Hirose T., Harigai M., Suzuki K., Kawakami M., Kawaguchi Y., Hidaka T., Kawagoe M., Nakamura H. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clin. Exp. Immunol. 88:1992;75-83.
29. Woolf T. M., Melton D. A., Jennings C. G. B. Specificity of antisense oligonucleotidesin vivo. Proc. Natl. Acad. Sci. USA. 89:1992;7305-7309.
30. Krieg A. M., Yi A., Matson S., Waldschmidt T. J., Bishop G. A., Teasdale R., Koretzky G. A., Klinman D. M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
31. Akhtar S., Kole R., Juliano R. L. Stability of antisense DNA oligodeoxynucleotides analogs in cellular extracts and sera. Life Sci. 49:1991;1793-1801.
32. Spiller D. G., Tidd D. M. Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabilization of human leukemia cells with streptolysin O. Antisense Res. Dev. 5:1995;13-21.
33. Agrawal S., Akhtar S. Advances in antisense efficacy and delivery. TIBTech. 13:1995;197-199.